Cardiff Oncology Inc (NASDAQ: CRDF) kicked off on Monday, up 12.34% from the previous trading day, before settling in for the closing price of $3.08. Over the past 52 weeks, CRDF has traded in a range of $0.94-$6.42.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 9.26% over the last five years. While this was happening, its average annual earnings per share was recorded -7.10%. With a float of $47.17 million, this company’s outstanding shares have now reached $51.13 million.
The firm has a total of 32 workers. Let’s measure their productivity. In terms of profitability, gross margin is 55.01%, operating margin of -6735.99%, and the pretax margin is -6239.04%.
Cardiff Oncology Inc (CRDF) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cardiff Oncology Inc is 7.76%, while institutional ownership is 23.86%. The most recent insider transaction that took place on Dec 19 ’23, was worth 41,100. In this transaction Director of this company bought 30,000 shares at a rate of $1.37, taking the stock ownership to the 697,761 shares.
Cardiff Oncology Inc (CRDF) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -7.10% per share during the next fiscal year.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Take a look at Cardiff Oncology Inc’s (CRDF) current performance indicators. Last quarter, stock had a quick ratio of 4.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 193.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.95, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.98 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Analysing the last 5-days average volume posted by the [Cardiff Oncology Inc, CRDF], we can find that recorded value of 1.82 million was better than the volume posted last year of 0.95 million. As of the previous 9 days, the stock’s Stochastic %D was 45.19%. Additionally, its Average True Range was 0.39.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 61.18%, which indicates a significant increase from 44.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 152.84% in the past 14 days, which was higher than the 86.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.76, while its 200-day Moving Average is $3.05. Now, the first resistance to watch is $3.71. This is followed by the second major resistance level at $3.97. The third major resistance level sits at $4.27. If the price goes on to break the first support level at $3.16, it is likely to go to the next support level at $2.86. Now, if the price goes above the second support level, the third support stands at $2.60.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
The company with the Market Capitalisation of 133.23 million has total of 46,550K Shares Outstanding. Its annual sales at the moment are 490 K in contrast with the sum of -41,440 K annual income. Company’s last quarter sales were recorded 160 K and last quarter income was -11,780 K.
